IONIS PHARMACEUTICALS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IONIS PHARMACEUTICALS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $203.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $226.58M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $324.51M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $151.89M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $440.01M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $290.28M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $493.68M | Feb 24, 2021 |
| FY2019 | Sep 30, 2019 | $167.89M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $163.81M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $297.21M | Mar 2, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $943.71M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $705.14M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $787.65M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $587.37M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $810.46M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $729.26M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $1.12B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $599.67M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $514.18M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $372.78M | Mar 1, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($229.39M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($104.35M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($9.26M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($52.43M) | Feb 21, 2024 |
| FY2021 | Dec 31, 2021 | $224.61M | Feb 25, 2022 |
| FY2021 | Dec 31, 2020 | ($354.53M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $184.42M | Feb 24, 2021 |
| FY2019 | Sep 30, 2019 | $26.16M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | ($876.0K) | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $84.44M | Mar 2, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($214.46M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($110.82M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($6.12M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($208.02M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $220.60M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | ($22.66M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $260.65M | Feb 24, 2021 |
| FY2019 | Sep 30, 2019 | $2.52M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | ($18.83M) | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $121.54M | Mar 2, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $915.62M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $901.53M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $899.63M | Feb 26, 2026 |
| FY2021 | Dec 31, 2021 | $638.20M | Feb 25, 2022 |
| FY2021 | Dec 31, 2020 | $531.00M | Feb 25, 2022 |
| FY2021 | Dec 31, 2019 | $461.50M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $411.90M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $372.50M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $340.40M | Mar 1, 2019 |
| FY2017 | Dec 31, 2015 | $319.50M | Feb 28, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $393.87M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $267.47M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $232.62M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $150.30M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $186.35M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $354.32M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $286.64M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $244.62M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $108.49M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $48.62M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($268.58M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($500.95M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($307.51M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($274.37M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $30.80M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $35.89M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $345.63M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $602.91M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $174.15M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($112.11M) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.44M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $45.28M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $23.81M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $15.72M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $11.96M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $35.12M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $30.91M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $13.61M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $34.76M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $7.11M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.52B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.00B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.99B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $2.53B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $2.61B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $2.39B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $3.23B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $2.67B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.32B | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $912.47M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.03B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.42B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.60B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.96B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.84B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.65B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.55B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.48B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $957.49M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $812.90M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $489.09M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $588.35M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $386.69M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $572.89M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $771.74M | Feb 19, 2025 |
| FY2023 | Dec 31, 2020 | $743.28M | Feb 21, 2024 |
| FY2020 | Dec 31, 2019 | $1.47B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.05B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $281.01M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $99.57M | Feb 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.63B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($2.25B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($1.80B) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($1.43B) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($1.16B) | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | ($1.13B) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($707.53M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($967.29M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($1.24B) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($1.18B) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $372.26M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $242.08M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $399.27M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $276.47M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $869.19M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $397.66M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $683.29M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $278.82M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $129.63M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $84.69M | Mar 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.81B | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | $1.25B | Feb 19, 2025 |
| FY2023 | Dec 31, 2023 | $1.31B | Feb 21, 2024 |
| FY2022 | Dec 31, 2022 | $1.19B | Feb 22, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 1 | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 1 | Feb 24, 2021 |
| FY2019 | Sep 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 1 | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 1 | Feb 24, 2021 |
| FY2019 | Sep 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 163.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 157.91M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 144.34M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 142.06M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 141.21M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 140.37M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 140.34M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 137.93M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 124.98M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 121.64M | Feb 28, 2018 |